Suppression of the antibody response to sulfolipids in leprosy patients by 4,4'-diaminodiphenyl sulfone (DDS).
Antibodies to sulfolipids were demonstrated in patients suffering from lepromatous leprosy. The antibody titre was found to decrease gradually on treatment with DDS. This effect was maximum for patients undergoing treatment for more than 1 year.
D000906:Antibodies / Q000276:immunology*; D000917:Antibody Formation / Q000187:drug effects; D003622:Dapsone / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007918:Leprosy / Q000188:drug therapy / Q000276:immunology*; D008055:Lipids / Q000276:immunology*; D009166:Mycobacterium leprae / Q000276:immunology
D000906:Antibodies; D008055:Lipids; C015518:sulfolipids; D003622:Dapsone